Deals
Novartis and Unnatural Products did not specify which disease targets they’re going after, only noting that the latter’s macrocyclic platform can generate potentially next-generation therapies that could apply to cardiovascular conditions.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The Silicon Therapeutics acquisition is designed to complement Roivant’s targeted protein degradation platform.
While public perception of the pharmaceutical industry is on an upswing among the general population due to rapid vaccine and therapeutic development during the COVID-19 pandemic, in the eyes of credit rating agencies, the industry is on a continued downward spiral.
Merck said the acquisition adds a pipeline of drug candidates that target a broad range of autoimmune diseases.
CDMO Catalent continues its push to the top with yet another acquisition. Buying out Delphi Genetics, the manufacturing company can now add plasmid DNA production to its growing list of offerings.
Charles River Laboratories will acquire Cognate BioServices in an $875 million cash deal that will significantly expand the company’s capabilities in the high-growth cell and gene therapy sector.
According to NASDAQ, SPACs – Special Purpose Acquisition Companies – now make up more than a third of all IPOs.
The combined company will be called Gemini Therapeutics, Inc. and will trade under the ticker symbol, GMTX.
Innate immune-oncology company Bolt expects to raise $230 million, and cancer cell therapy player Vor Biopharma expects to raise $176.9 million, in upsized initial public offerings (IPOs) starting today, following yesterday’s $587.5 million IPO for Sana Biotechnology and other financing news this week.
Sana Biotechnology led the way with a very large initial public offering that could bring the company’s market value to $4.6 billion or more. But it’s not the only IPO this week. Here’s a look.
Jazz Pharmaceuticals will beef up its neurology pipeline with a $7.2 billion buyout of GW Pharmaceuticals, the only company yet to score U.S. regulatory approval for a cannabis-derived product.